
Beta Bionics, Inc.: shareholders and insiders
Price
$14.33
November 18, 2026Market cap $779M
What Ploutos Investor adds for Beta Bionics
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 33% since Oct 27, 2026, when the 10-Q these figures come from was filed ($21.39 then, $14.33 on Nov 18, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$4.8M
8 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan69%
- The rest31%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $5.1M by 7 people
- 2025: no buys, sold $370.7K by 7 people
- 2026: no buys, sold $5.1M by 7 people
- Nov 16, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Nov 16, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Nov 11, 2026Stephen FeiderChief Financial OfficerKind10b5-1
- Nov 11, 2026Stephen FeiderChief Financial OfficerKind10b5-1
- Nov 9, 2026Stephen FeiderChief Financial OfficerKind10b5-1
- Nov 9, 2026Stephen FeiderChief Financial OfficerKind10b5-1
- Nov 5, 2026Stephen FeiderChief Financial OfficerKind10b5-1
- Nov 5, 2026Stephen FeiderChief Financial OfficerKind10b5-1
- Nov 2, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Oct 27, 2026Mike MensingerChief Product OfficerKind10b5-1
- Oct 26, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Oct 14, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Oct 1, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Sep 22, 2026Christy JonesDirectorKind10b5-1
- Sep 16, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Sep 16, 2026Mike MensingerChief Product OfficerKind10b5-1
- Sep 14, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Sep 9, 2026Mark HopmanChief Commercial OfficerKind10b5-1
- Sep 3, 2026Sean SaintPresident & CEOKind10b5-1
- Sep 2, 2026Mark HopmanChief Commercial OfficerKind
- Sep 2, 2026Steven Jon RussellChief Medical OfficerKind
- Sep 2, 2026Mike MensingerChief Product OfficerKind
- Sep 2, 2026Stephen FeiderChief Financial OfficerKind
- Sep 2, 2026Sean SaintPresident & CEOKind
- Jun 29, 2026Stephen FeiderChief Financial OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 775 | $5.10 | $4.0K | Form 4 |
| Nov 16, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 775 | $16.22 | $12.6K | Form 4 |
| Nov 11, 2026 | Stephen FeiderChief Financial Officer | 10b5-1 | 8,874 | $5.10 | $45.3K | Form 4 |
| Nov 11, 2026 | Stephen FeiderChief Financial Officer | 10b5-1 | 8,874 | $17.21 | $152.7K | Form 4 |
| Nov 9, 2026 | Stephen FeiderChief Financial Officer | 10b5-1 | 744 | $5.10 | $3.8K | Form 4 |
| Nov 9, 2026 | Stephen FeiderChief Financial Officer | 10b5-1 | 744 | $17.00 | $12.6K | Form 4 |
| Nov 5, 2026 | Stephen FeiderChief Financial Officer | 10b5-1 | 382 | $5.10 | $1.9K | Form 4 |
| Nov 5, 2026 | Stephen FeiderChief Financial Officer | 10b5-1 | 382 | $17.04 | $6.5K | Form 4 |
| Nov 2, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 370 | $16.90 | $6.3K | Form 4 |
| Oct 27, 2026 | Mike MensingerChief Product Officer | 10b5-1 | 2,650 | $22.00 | $58.3K | Form 4 |
| Oct 26, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 821 | $20.00 | $16.4K | Form 4 |
| Oct 14, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 775 | $17.35 | $13.4K | Form 4 |
| Oct 1, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 370 | $18.96 | $7.0K | Form 4 |
| Sep 22, 2026 | Christy JonesDirector | 10b5-1 | 6,430 | $23.00 | $147.9K | Form 4 |
| Sep 16, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 30.8K | $20.13 | $619.6K | Form 4 |
| Sep 16, 2026 | Mike MensingerChief Product Officer | 10b5-1 | 2,650 | $22.00 | $58.3K | Form 4 |
| Sep 14, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 775 | $15.52 | $12.0K | Form 4 |
| Sep 9, 2026 | Mark HopmanChief Commercial Officer | 10b5-1 | 36.9K | $18.46 | $680.7K | Form 4 |
| Sep 3, 2026 | Sean SaintPresident & CEO | 10b5-1 | 5,641 | $20.08 | $113.3K | Form 4 |
| Sep 2, 2026 | Mark HopmanChief Commercial Officer | 5,327 | $19.11 | $101.8K | Form 4 | |
| Sep 2, 2026 | Steven Jon RussellChief Medical Officer | 4,221 | $19.11 | $80.7K | Form 4 | |
| Sep 2, 2026 | Mike MensingerChief Product Officer | 4,375 | $19.11 | $83.6K | Form 4 | |
| Sep 2, 2026 | Stephen FeiderChief Financial Officer | 6,675 | $19.11 | $127.6K | Form 4 | |
| Sep 2, 2026 | Sean SaintPresident & CEO | 16.9K | $19.11 | $322.4K | Form 4 | |
| Jun 29, 2026 | Stephen FeiderChief Financial Officer | 10b5-1 | 4,896 | $5.10 | $25.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 26, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by BBNX's officers and directors from 2025 up to November 18, 2025, 1 more calendar year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 2 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- T. Rowe Price Associates, Inc.Share of class16.6%
- Eventide Asset Management, LLCwith 2 more personsShare of class13.4%
- Soleus Private Equity Fund II, L.P.with 8 more personsShare of class8.70%
- Morgan Stanleywith 1 more personShare of class8.60%
- Sands Capital Life Sciences Pulse Fund II. L.P.with 2 more personsShare of class8.20%
- Divisadero Street Capital Management, LPwith 4 more personsShare of class6.90%
- BlackRock, Inc.Share of class6.40%
- Point72 Asset Management, L.P.with 2 more personsShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 16.6% | 8.94M | Oct 7, 2026 | 13G | |
| Eventide Asset Management, LLCwith 2 more persons | 13.4% | 5.95M | May 15, 20262 filings since Feb 5, 2025 | 13G/A | |
| Soleus Private Equity Fund II, L.P.with 8 more persons | 8.70% | 4.83M | Nov 9, 20264 filings since May 2, 2025 | 13G/A | |
| Morgan Stanleywith 1 more person | 8.60% | 3.74M | Nov 7, 20252 filings since Aug 7, 2025 | 13G/A | |
| Sands Capital Life Sciences Pulse Fund II. L.P.with 2 more persons | 8.20% | 3.57M | Aug 13, 20252 filings since Apr 9, 2025 | 13G/A | |
| Divisadero Street Capital Management, LPwith 4 more persons | 6.90% | 3.07M | Jul 24, 2026 | 13G | |
| BlackRock, Inc. | 6.40% | 2.78M | Oct 17, 2025 | 13G | |
| Point72 Asset Management, L.P.with 2 more persons | 5.20% | 2.29M | Feb 23, 2026 | 13G |
Fell to 5% or less (7)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Farallon Capital Management, L.L.C.1.30%Aug 13, 202613G/A
- RTW Investments, LP4.50%May 15, 202613G/A
- The Vanguard Group0.00%Mar 26, 202613G/A
- Wellington Hadley Harbor Aggregator IV, L.P.0.00%Feb 10, 202613G/A
- Wellington Management Group LLP0.00%Feb 10, 202613G/A
- Millennium Management LLC1.80%Oct 16, 202513G/A
- Perceptive Advisors LLC3.68%Aug 7, 202513G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter-57%
- D.E. ShawIn the quarter
- Citadel Advisors (Griffin)In the quarter
- Millennium Mgmt (Englander)In the quarter-98%
- Renaissance TechnologiesIn the quarter+445%
- AQR CapitalIn the quarter+1.2%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 967.1K | -57% | $18M | 0.03% |
| D.E. Shaw | 781.1K | $15M | 0.01% | |
| Citadel Advisors (Griffin) | 103.5K | $2.0M | 0.00% | |
| Millennium Mgmt (Englander) | 15.9K | -98% | $300.0K | 0.00% |
| Renaissance Technologies | 61.6K | +445% | $1.2M | 0.00% |
| AQR Capital | 312.1K | +1.2% | $5.9M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 12.7% of its shares outstanding were held short, +14.4% since the report before.
- Shares held short
- 6.92M
- 12.7%
- Since the report before6.05M on Sep 30, 2026
- +14.4%
- 7.4
- 936.8K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 80%
- Report date
- Oct 15, 2026
- Shares held short
- Jan 31, 2025: Shares held short 209.3K
- Feb 14, 2025: Shares held short 945.1K
- Feb 28, 2025: Shares held short 1.18M
- Mar 14, 2025: Shares held short 1.21M
- Mar 31, 2025: Shares held short 3.14M
- Apr 15, 2025: Shares held short 3.39M
- Apr 30, 2025: Shares held short 3.54M
- May 15, 2025: Shares held short 3.56M
- May 30, 2025: Shares held short 4.13M
- Jun 13, 2025: Shares held short 4.73M
- Jun 30, 2025: Shares held short 4.90M
- Jul 15, 2025: Shares held short 4.80M
- Jul 31, 2025: Shares held short 4.19M
- Aug 15, 2025: Shares held short 2.67M
- Aug 29, 2025: Shares held short 3.11M
- Sep 15, 2025: Shares held short 3.88M
- Sep 30, 2025: Shares held short 6.38M
- Oct 15, 2025: Shares held short 4.17M
- Oct 31, 2025: Shares held short 3.60M
- Nov 14, 2025: Shares held short 3.57M
- Nov 28, 2025: Shares held short 3.86M
- Dec 15, 2025: Shares held short 4.02M
- Dec 31, 2025: Shares held short 7.30M
- Jan 15, 2026: Shares held short 5.55M
- Jan 30, 2026: Shares held short 5.48M
- Feb 13, 2026: Shares held short 5.75M
- Feb 27, 2026: Shares held short 5.63M
- Mar 13, 2026: Shares held short 7.01M
- Mar 31, 2026: Shares held short 7.60M
- Apr 15, 2026: Shares held short 7.14M
- Apr 30, 2026: Shares held short 6.19M
- May 15, 2026: Shares held short 5.69M
- May 29, 2026: Shares held short 5.20M
- Jun 15, 2026: Shares held short 4.67M
- Jun 30, 2026: Shares held short 6.82M
- Jul 15, 2026: Shares held short 6.61M
- Jul 31, 2026: Shares held short 7.60M
- Aug 14, 2026: Shares held short 7.49M
- Aug 31, 2026: Shares held short 9.40M
- Sep 15, 2026: Shares held short 10.62M
- Sep 30, 2026: Shares held short 6.05M
- Oct 15, 2026: Shares held short 6.92M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading48.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 48.7% of the shares in the reported trades were short sales, against 66.1% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 48.7%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 66.1%
- Change
- -17.4 pts
- Short sales a dayon average, of 410.9K shares
- 200.0K
- More than atof 3,656 US-listed companies, same days
- 44%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 62.3%
- Oct 13, 2026: Short sales 74.6%
- Oct 14, 2026: Short sales 63.8%
- Oct 15, 2026: Short sales 71.6%
- Oct 16, 2026: Short sales 79%
- Oct 19, 2026: Short sales 85.4%
- Oct 20, 2026: Short sales 46.7%
- Oct 21, 2026: Short sales 62.5%
- Oct 22, 2026: Short sales 73.8%
- Oct 23, 2026: Short sales 63.4%
- Oct 26, 2026: Short sales 63.4%
- Oct 27, 2026: Short sales 48.4%
- Oct 28, 2026: Short sales 76.2%
- Oct 29, 2026: Short sales 60.6%
- Oct 30, 2026: Short sales 49.1%
- Nov 2, 2026: Short sales 59.6%
- Nov 3, 2026: Short sales 71.8%
- Nov 4, 2026: Short sales 44.6%
- Nov 5, 2026: Short sales 45.4%
- Nov 6, 2026: Short sales 55.5%
- Nov 9, 2026: Short sales 36.6%
- Nov 10, 2026: Short sales 38.9%
- Nov 11, 2026: Short sales 35.4%
- Nov 12, 2026: Short sales 52.6%
- Nov 13, 2026: Short sales 35.5%
- Nov 16, 2026: Short sales 55.9%
- Nov 17, 2026: Short sales 57.1%
- Nov 18, 2026: Short sales 51.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Wellington Hadley Harbor Aggregator IV, L.P.TenPercentOwnerDirectly3.90M
- Sean SaintPresident & CEODirectly398.4K
- Mike MensingerChief Product OfficerDirectly174.7K
- Steven Jon RussellChief Medical OfficerDirectly169.6K
- Stephen FeiderChief Financial OfficerDirectly159.4K
- Mark HopmanChief Commercial OfficerDirectly54.1K
- Gerard J MichelDirectorDirectly33.5K
- Danny L. DearenDirectorDirectly32.2K
- Sean CarneyDirectorDirectly32.2K
- Maria PalasisDirectorDirectly29.4K
- Adam LezackDirectorDirectly27.4K
- Christy JonesDirectorDirectly19.6K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Wellington Hadley Harbor Aggregator IV, L.P.TenPercentOwner | 3.90M | – | Jan 31, 2025 | Form 4 |
| Sean SaintPresident & CEO | 398.4K | – | Sep 3, 2026 | Form 4 |
| Mike MensingerChief Product Officer | 174.7K | – | Oct 27, 2026 | Form 4 |
| Steven Jon RussellChief Medical Officer | 169.6K | – | Sep 2, 2026 | Form 4 |
| Stephen FeiderChief Financial Officer | 159.4K | – | Nov 11, 2026 | Form 4 |
| Mark HopmanChief Commercial Officer | 54.1K | – | Nov 16, 2026 | Form 4 |
| Gerard J MichelDirector | 33.5K | – | May 21, 2026 | Form 4 |
| Danny L. DearenDirector | 32.2K | – | May 21, 2026 | Form 4 |
| Sean CarneyDirector | 32.2K | – | May 21, 2026 | Form 4 |
| Maria PalasisDirector | 29.4K | – | May 21, 2026 | Form 4 |
| Adam LezackDirector | 27.4K | – | May 22, 2026 | Form 4 |
| Christy JonesDirector | 19.6K | – | Sep 22, 2026 | Form 4 |
A lower bound: it counts only the 12 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHIiShares U.S. Medical Devices ETFWeight in the fund0.10%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.04%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- SCHBSchwab U.S. Broad Market ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
- ITOTiShares Core S&P Total U.S. Stock Market ETFWeight in the fund0.00%
- IWViShares Russell 3000 ETFWeight in the fund0.00%
13 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 129
- Q4 2025: Managers 158
- Q1 2026: Managers 132
- Q2 2026: Managers 134
Institutional investors by quarter
The fund managers holding BBNX, quarter by quarter, from Q1 2025 to Q2 2025, 2 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 6 quarters.
Q2 2026: 134 managers held 47.97M shares, worth $752M. During the quarter 30 opened a position, 28 closed one, 54 added and 33 trimmed.
The largest holders, Q2 2026
- Eventide Asset ManagementIn the quarter+5.2%
- Soleus Capital ManagementIn the quarter+0.9%
- Morgan StanleyIn the quarter+0.9%
- Sands Capital AlternativesIn the quarter
- BlackRockIn the quarter+9.9%
- Point72 (Cohen)In the quarter-11%
- Vanguard Capital ManagementIn the quarter+3.1%
- Vestal Point CapitalIn the quarter-28%
- Rtw InvestmentsIn the quarter-25%
- Deerfield ManagementIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Eventide Asset Management | 6.25M | +5.2% | $98M |
| Soleus Capital Management | 4.39M | +0.9% | $69M |
| Morgan Stanley | 4.27M | +0.9% | $67M |
| Sands Capital Alternatives | 3.71M | $58M | |
| BlackRock | 3.34M | +9.9% | $52M |
| Point72 (Cohen) | 2.25M | -11% | $35M |
| Vanguard Capital Management | 1.78M | +3.1% | $28M |
| Vestal Point Capital | 1.60M | -28% | $25M |
| Rtw Investments | 1.50M | -25% | $24M |
| Deerfield Management | 1.32M | $21M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Beta Bionics's filings show?
Who buys and sells is one part of Beta Bionics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have BBNX's insiders bought or sold?
From May 26, 2026 to Nov 18, 2026 Beta Bionics's insiders bought 0 and sold $3.4M of shares on the market. 65% of the sales were under set 10b5-1 plans.
Which well-known managers hold BBNX?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $18M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.